P-ISSN 2587-2400 | E-ISSN 2587-196X

About Journal

About Journal

P-ISSN 2587-2400 | E-ISSN 2587-196X

Abstracting and Indexing
Emerging Sources Citation Index (web of science) (ESCI) since 2020
SCOPUS since 2021
EBSCO since 2019
ProQuest since 2019
CNKI since 2020
CINAHL since 2020
TR DIZIN since 2019

WEB OF SCIENCE click

  • Impact Factor: 0.8
  • Medicine, General & Internal: Q2 146/322

  • SCOPUS click

  • CiteScoreTracker 2023: 5.6
  • CiteScore year 2022: 0.9
  • CiteScore year 2021: 0.2



  • Aims and Scope
    Aim of the journal is to publish qualified research material on its scope. The target readership includes academic members or specialists on medicine and oncology. Scope of the journal covers medicine and oncology.
    EJMO publishes articles following a double-blind peer review mechanism to ensure the standards of its publications.
    EJMO selects generally from Reviewers situated in ScholarOne-Publons. The Eurasian Journal of Medicine and Oncology (EJMO) is published every three months (March, June, September, December)

    Abbreviation
    Eurasian J Med Oncol

    Publication Fees
    An article processing charge (APC) of USD 1650 applies to papers accepted after peer review.

    Revenue sources

    Digital archiving and preservation policy
    If journal stops publishing : We intend and expect to continue to publish our journal for a very long time. If, due to some rare, unfortunate circumstances, we are forced to stop publishing the journal, the manuscripts published in the journal will be kept online and accessible to the readers through TUBITAK (TUBITAK is an institution of Republic Of Turkey Ministry of Industry and Technology) and Turkish Medline National Health Sciences Periodicals Database TURKMEDLINE

    Basic Publication Rules
    Authors are responsible for the accuracy of data and the journal is in compliance with the uniform requirements for manuscripts submitted to biomedical journals published by the International Committee of Medical Journal Editors (ICMJE). The editorial and publication processes of the journal are conducted in accordance with the guidelines of the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the European Association of Science Editors (EASE), and the Committee on Publication Ethics (COPE) as well.

    Disclaimer

    Statements or opinions expressed in the manuscripts published in Eurasian Journal of Medical Investigation reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

    Basic Language Rules
    If you are author not a native English speaker, we recommend that you have your manuscript professionally edited before submission or read by a native English-speaking colleague. we recommend that you get this service from https://www.scribendi.com/service/academic_proofreading or https://www.aje.com/?rcode=s1manuscripts

    Disclaimer
    Statements or opinions expressed in the manuscripts published in Eurasian Journal of Medicine and Oncology reflect the views of the author(s) and not the opinions of the editors, the editorial board and the publisher; the editors, the editorial board and the publisher disclaim any responsibility or liability for such materials.

    Access to Journal Content
    The abstracts and full texts of published articles can be accessed free of charge at www.ejmo.org www.ejmo.org

    Editor

    Hilmi Kodaz, Md.
    Department of Medical Oncology, Eskisehir, Turkey
    Phone:
    +905079314286 E-mail: hilmikodaz@hotmail.com and editor@ejmo.org

    Publisher

    AccScience Publishing
    AccScience Publishing 8 Burn Road#15-03 Trivex Singapore 369977 Office Hours: 9:00-17:00 (GMT +8)


    Web : www.accscience.com
    E-mail: editorial@accscience.com

    WEB OF SCIENCE click

  • Impact Factor: 0.8

  • Medicine, General & Internal: Q2 146/322


  • SCOPUS click

  • CiteScoreTracker 2023: 5.6
  • CiteScore year 2022:
    0.9
  • CiteScore year 2021:
    0.2


  • Google Scholar click

  • Number of Articles:315
  • Citations:2587
  • h-index:16
  • i10-index:=26

  • EJMO NLM ID: 101720527

  • Accept Ratio :18.2 %
  • Final decision avg 34 day
  • EJMO & EJMO